Kazuho Inoko
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kazuho Inoko has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Satoshi Hirano
Department of Gastroenterological Surgery II, Hokkaido University Faculty of Medicine, Sapporo, Japan
12 shared publications - Takahiro Tsuchikawa
Department of Gastroenterological Surgery II, Hokkaido University Faculty of Medicine, Sapporo 060-8638, Japan
12 shared publications - Toshiaki Shichinohe
Department of Gastroenterological Surgery II, Hokkaido University Faculty of Medicine, Sapporo, Japan
12 shared publications Katsunori Sasaki
Department of Gastroenterological Surgery II, Hokkaido University Faculty of Medicine, Sapporo, Japan
11 shared publications- Takehiro Noji
Department of Gastroenterological Surgery II, Faculty of Medicine, Hokkaido University, Sapporo, Japan
11 shared publications - Keisuke Okamura
Department of Cardiology and Cardiovascular Center, Imamura Hospital, Tosu, Japan
10 shared publications
Latest Publications
- 23 July 2024
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 31 (9) , 1390-1401
Therapeutic activity of retroviral replicating vector-mediated gene therapy in combination with anti-PD-1 antibody in a murine pancreatic cancer model
Toca 511, a tumor-selective retroviral replicating vector encoding the yeast cytosine deaminase (yCD) gene, exerts direct antitumor effects through intratumoral prodrug 5-fluorocytosine (5-FC) conversion to active drug 5-fluorouracil by yCD, and has demonstrated therapeutic efficacy in preclinical and clinical trials of various cancers. Toca 511/5-FC treatment may also induce antitumor immunity. Here, we first examined antitumor immune responses activated by Toca 511/5-FC treatment in an immunocompetent murine pancreatic cancer model. We then evaluated the therapeutic effects achieved in combination with anti-programmed cell death protein 1 antibody. In the bilateral subcutaneous tumor model, as compared with the control group, enhanced CD8+ T-cell-mediated cytotoxicity and increased T-cell infiltration in Toca 511-untransduced contralateral tumors were observed. Furthermore, the expression levels of T-cell co-inhibitory receptors on CD8+ T-cells increased during treatment. In the bilateral subcutaneous tumor model, combination therapy showed significantly stronger tumor growth inhibition than that achieved with either monotherapy. In an orthotopic tumor and peritoneal dissemination model, the combination therapy resulted in complete regression in both transduced orthotopic tumors and untransduced peritoneal dissemination. Thus, Toca 511/5-FC treatment induced a systemic antitumor immune response, and the combination therapy could be a promising clinical strategy for treating metastatic pancreatic cancer.
- 23 July 2024
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 31 (9) , 1390-1401
Therapeutic activity of retroviral replicating vector-mediated gene therapy in combination with anti-PD-1 antibody in a murine pancreatic cancer model
Toca 511, a tumor-selective retroviral replicating vector encoding the yeast cytosine deaminase (yCD) gene, exerts direct antitumor effects through intratumoral prodrug 5-fluorocytosine (5-FC) conversion to active drug 5-fluorouracil by yCD, and has demonstrated therapeutic efficacy in preclinical and clinical trials of various cancers. Toca 511/5-FC treatment may also induce antitumor immunity. Here, we first examined antitumor immune responses activated by Toca 511/5-FC treatment in an immunocompetent murine pancreatic cancer model. We then evaluated the therapeutic effects achieved in combination with anti-programmed cell death protein 1 antibody. In the bilateral subcutaneous tumor model, as compared with the control group, enhanced CD8+ T-cell-mediated cytotoxicity and increased T-cell infiltration in Toca 511-untransduced contralateral tumors were observed. Furthermore, the expression levels of T-cell co-inhibitory receptors on CD8+ T-cells increased during treatment. In the bilateral subcutaneous tumor model, combination therapy showed significantly stronger tumor growth inhibition than that achieved with either monotherapy. In an orthotopic tumor and peritoneal dissemination model, the combination therapy resulted in complete regression in both transduced orthotopic tumors and untransduced peritoneal dissemination. Thus, Toca 511/5-FC treatment induced a systemic antitumor immune response, and the combination therapy could be a promising clinical strategy for treating metastatic pancreatic cancer.
- Open Access
Viral Shedding in Mice following Intravenous Adenovirus Injection: Impact on Biosafety Classification
There have been numerous advances in gene therapy and oncolytic virotherapy in recent years, especially with respect to cutting-edge animal models to test these novel therapeutics. With all of these advances, it is important to understand the biosafety risks of testing these vectors in animals. We performed adenovirus-based viral shedding studies in murine models to ascertain when it is appropriate to downgrade the animals from Biosafety Level (BSL) 2 to BSL 1 for experimental handling and transport. We utilized intravenous injections of a replication-competent adenovirus and analyzed viral shedding via the collection of buccal and dermal swabs from each animal, in addition to obtaining urine and stool samples. The adenovirus hexon copy number was determined by qPCR, and plaque formation was analyzed to assess the biologic activity of viral particles. Our results demonstrate that after 72 h following viral inoculation, there is no significant quantity of biologically active virus shedding from the animals. This observation suggests that on day 4 following adenovirus injection, mice can be safely downgraded to BSL 1 for the remainder of the experiment with no concern for hazardous exposure to laboratory personnel.
Open AccessViral Shedding in Mice following Intravenous Adenovirus Injection: Impact on Biosafety Classification
There have been numerous advances in gene therapy and oncolytic virotherapy in recent years, especially with respect to cutting-edge animal models to test these novel therapeutics. With all of these advances, it is important to understand the biosafety risks of testing these vectors in animals. We performed adenovirus-based viral shedding studies in murine models to ascertain when it is appropriate to downgrade the animals from Biosafety Level (BSL) 2 to BSL 1 for experimental handling and transport. We utilized intravenous injections of a replication-competent adenovirus and analyzed viral shedding via the collection of buccal and dermal swabs from each animal, in addition to obtaining urine and stool samples. The adenovirus hexon copy number was determined by qPCR, and plaque formation was analyzed to assess the biologic activity of viral particles. Our results demonstrate that after 72 h following viral inoculation, there is no significant quantity of biologically active virus shedding from the animals. This observation suggests that on day 4 following adenovirus injection, mice can be safely downgraded to BSL 1 for the remainder of the experiment with no concern for hazardous exposure to laboratory personnel.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplemental figure 3 from Role of Dimerized C16orf74 in Aggressive Pancreatic Cancer: A Novel Therapeutic Target
Supplemental Figure 3 shows matrigel invasion assay of C16orf74 stable cell lines (Clone C16-A. C16-B. C16-C) with 11R-DB administration and no administration. In the administered group, the invasion was significantly suppressed. * P<0.05
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental figure 3 from Role of Dimerized C16orf74 in Aggressive Pancreatic Cancer: A Novel Therapeutic Target
Supplemental Figure 3 shows matrigel invasion assay of C16orf74 stable cell lines (Clone C16-A. C16-B. C16-C) with 11R-DB administration and no administration. In the administered group, the invasion was significantly suppressed. * P<0.05
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplemental Table 5 from Role of Dimerized C16orf74 in Aggressive Pancreatic Cancer: A Novel Therapeutic Target
RT-PCR primers for construction of the expression vectors
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 5 from Role of Dimerized C16orf74 in Aggressive Pancreatic Cancer: A Novel Therapeutic Target
RT-PCR primers for construction of the expression vectors
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplemental figure 1 from Role of Dimerized C16orf74 in Aggressive Pancreatic Cancer: A Novel Therapeutic Target
Supplemental Figure 1 shows, (A) analysis of expression of C16orf74 in C16orf74 stable and MOCK cell lines by qRT-PCR, (B) expression of C16orf74 in C16orf74 stable and MOCK by Western blotting, (C) expression of C16orf74 in C16orf74 stable clonal cell lines by Immunofluorescence. C16orf74 localizes under the cell membrane, and (D) expression of endogenous C16orf74 protein in PK-9 cells shown by Immunofluorescence. Endogenous C16orf74 localizes under the cell membrane.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental figure 1 from Role of Dimerized C16orf74 in Aggressive Pancreatic Cancer: A Novel Therapeutic Target
Supplemental Figure 1 shows, (A) analysis of expression of C16orf74 in C16orf74 stable and MOCK cell lines by qRT-PCR, (B) expression of C16orf74 in C16orf74 stable and MOCK by Western blotting, (C) expression of C16orf74 in C16orf74 stable clonal cell lines by Immunofluorescence. C16orf74 localizes under the cell membrane, and (D) expression of endogenous C16orf74 protein in PK-9 cells shown by Immunofluorescence. Endogenous C16orf74 localizes under the cell membrane.